Last reviewed · How we verify
Aripiprazole oral product
At a glance
| Generic name | Aripiprazole oral product |
|---|---|
| Also known as | Abilify |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Somnolence
- Weight increased
- Headache
- Nausea
- Increased appetite
- Obesity
- Medical device site irritation
Key clinical trials
- Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone (PHASE1)
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT) (PHASE3)
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression (PHASE3)
- VA Aripiprazole vs Esketamine for Treatment Resistant Depression (PHASE4)
- Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode (PHASE4)
- Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands) (PHASE1)
- Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aripiprazole oral product CI brief — competitive landscape report
- Aripiprazole oral product updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI